In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lorus acquires GeneSense in stock deal

Executive Summary

Lorus Therapeutics will acquire privately held GeneSense Technologies (antisense cancer drugs) in an all-stock transaction, with the goal of creating Canada's leading cancer biopharmaceutical company.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock
    • Intra-Biotech Deal

Related Companies

UsernamePublicRestriction

Register